Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Heron Therapeutics (HRTX) PT Lowered to $34 at Cowen; Launch Likely Pushed to Mid-2021
June 29, 2020 10:56 AM EDTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $34.00 (from $39.00) while maintaining an Outperform rating.
The analyst commented, "Heron received a CRL for HTX-011 requesting additional nonclinical information. The CRL is related to excipient exposure levels from... More
Heron Therapeutics (HRTX) said defended at Evercore ISI
June 29, 2020 10:14 AM EDTHeron Therapeutics (NASDAQ: HRTX) said defended at Evercore ISI, saying they are buyers on weakness.
... MoreHeron Therapeutics (HRTX) to Resume Trading at 9:10 a.m.
June 29, 2020 8:48 AM EDTHeron Therapeutics (NASDAQ: HRTX) to Resume Trading at 9:10 a.m.
